Publicaciones en colaboración con investigadores/as de Novo Nordisk (16)

2024

  1. Adherence and Persistence to Basal Insulin Among People with Type 2 Diabetes in Europe: A Systematic Literature Review and Meta-analysis

    Diabetes Therapy, Vol. 15, Núm. 5, pp. 1047-1067

2023

  1. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

    Obesity, Vol. 31, Núm. 3, pp. 703-715

2022

  1. Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial

    Diabetes Therapy, Vol. 13, Núm. 4, pp. 761-774

  2. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

    Nature Medicine, Vol. 28, Núm. 10, pp. 2083-2091

2020

  1. Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: A comparison with general population, 2015

    BMJ Open Diabetes Research and Care, Vol. 8, Núm. 1

  2. Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

    Diabetes Therapy, Vol. 11, Núm. 5, pp. 1061-1075

  3. Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

    Diabetes, Obesity and Metabolism, Vol. 22, Núm. 8, pp. 1339-1347

  4. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

    Journal of Diabetes Science and Technology, Vol. 15, Núm. 3, pp. 636-645

2019

  1. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

    Cardiovascular Diabetology, Vol. 18, Núm. 1

  2. Cost of achieving hba1c and weight loss treatment targets with ideglira vs insulin glargine u100 plus insulin aspart in the usa

    ClinicoEconomics and Outcomes Research, Vol. 11, pp. 271-282

  3. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

    Diabetes, Obesity and Metabolism, Vol. 21, Núm. 6, pp. 1506-1512

  4. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy

    Diabetes, Obesity and Metabolism, Vol. 21, Núm. 12, pp. 2643-2650

  5. Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects with Type 2 Diabetes on Semaglutide

    Journal of Clinical Endocrinology and Metabolism, Vol. 104, Núm. 9, pp. 4078-4086

2018

  1. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The dual VII randomized clinical trial

    Diabetes Care, Vol. 41, Núm. 5, pp. 1009-1016

  2. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

    Diabetes, Obesity and Metabolism, Vol. 20, Núm. 1, pp. 200-205

2016

  1. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

    New England Journal of Medicine, Vol. 375, Núm. 19, pp. 1834-1844